AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2548135
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg conjugated equine estrogens + placebo
Trial: 18182665
Drug: Weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly docetaxel plus prednisone (D1P)
Trial: 15795146
Drug: PCEA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA plus continuous background infusion (4 mL/h plus an hourly maximum of three 4‐mL boluses on demand, lock‐out time 20 min)
Trial: 15795146
Drug: Demand-only PCEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demand-only PCEA (hourly maximum of four 4‐mL boluses, lock‐out time 15 min)
Trial: 15795146
Drug: Both regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both regimens (PCEA plus continuous background infusion and demand-only PCEA)
Trial: 15795146
Drug: PCEA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA plus continuous background infusion
Trial: 7006557
Drug: Imipramine hydrochloride
RxNorm normalized name: Imipramine Hydrochloride
DrugBank: Imipramine (DB00458)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imipramine hydrochloride (pharmacotherapy)
Trial: 28301098
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg AER (under fasting conditions)
Trial: 28301098
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg AER (under fed conditions)
Trial: 28301098
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg CARP
Trial: 28301098
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg AER
Trial: 25400472
Drug: Perioperative restricted
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative restricted fluid therapy (R, n = 96)
Trial: 25400472
Drug: Perioperative standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative standard fluid therapy (S, n = 89)
Trial: 20482508
Drug: Buspirone (anxiolytic,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (anxiolytic, 5-HT(1A) partial agonist)
Trial: 20482508
Drug: Ritanserin (serotonergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritanserin (serotonergic drug)
Trial: 20482508
Drug: Ondansetron (5-HT(3)
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron (5-HT(3) antagonist)
Trial: 20482508
Drug: SSRIs (Selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRIs (Selective serotonin reuptake inhibitors)
Trial: 11879258
Drug: Erythromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (500 mg twice daily on days 2-6)
Trial: 11879258
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg once daily on days 2-4)
Trial: 10689656
Drug: Initial motivationally
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial motivationally based, four-session outpatient treatment; n = 67
Trial: 2518847
Drug: Mesasal tablets,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesasal tablets, 2 x 250 mg, fasting
Trial: 2518847
Drug: Mesasal tablets,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesasal tablets, 2 x 250 mg, fed
Trial: 2518847
Drug: Salazopyrin tablets,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salazopyrin tablets, 3 x 500 mg (corresponding to 576 mg 5‐ASA), fasting
Trial: 2518847
Drug: Mesasal suppository,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesasal suppository, 1 x 500 mg, fasting
Trial: 31495292
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg once then 850 mg twice daily for two weeks
Trial: 31495292
Drug: Metformin (double
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (double dose 1700 mg)
Trial: 31495292
Drug: Metformin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (single dose 850 mg)
Trial: 15886247
Drug: Metformin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (both doses)
Trial: 21291446
Drug: Mentoring (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentoring (treatment group)
Trial: 17082240
Drug: ACEi (trandolapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEi (trandolapril 2 mg/d)
Trial: 17082240
Drug: ndCCB (verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ndCCB (verapamil SR 240 mg/d)
Trial: 17082240
Drug: Veratran (trandolapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veratran (trandolapril 2 mg/d plus verapamil SR 180 mg/d)
Trial: 11704899
Drug: Integrated Psychological
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated Psychological Therapy Program (IPT)
Trial: 7924757
Drug: Indomethacin (repeated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (repeated doses)
Trial: 7924757
Drug: Indomethacin (third
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (third dose)
Trial: 2891365
Drug: Neostigmine 2.5
RxNorm normalized name: neostigmine 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 2.5 mg
Trial: 2891365
Drug: Neostigmine 5
RxNorm normalized name: neostigmine 5 mg/5 mL preservative-free intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 5 mg
Trial: 18579227
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (aspirin plus clopidogrel)
Trial: 29409488
Drug: Polydisperse pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polydisperse pMDI inhalation of salbutamol (400 μg)
Trial: 20683947
Drug: High-dose ursodeoxycholic
RxNorm normalized name: ursodeoxycholate
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ursodeoxycholic acid (UDCA) 23-28 mg/kg/day
Trial: 17630563
Drug: Protease inhibitor-based
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor-based antiretroviral therapy
Trial: 17630563
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (general)
Trial: 12697595
Drug: Ropivacaine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 15 mg plus morphine 150 micro g (RM group)
Trial: 12697595
Drug: Bupivacaine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 15 mg plus morphine 150 micro g (BM group)
Trial: 10823363
Drug: Hypericum (LI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum (LI 160) 600 mg/d for 1 week, then 900 mg/d for 6 weeks
Trial: 10823363
Drug: Sertraline 50
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 50 mg/d for 1 week, then 75 mg/d for 6 weeks
Trial: 9032863
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose Gamma Knife treatment (surface dose 58 +/- 9 Gy, maximum dose 81 +/- 15 Gy, mean dose 66 +/- 11 Gy) in Group A (10 patients, follow-up 24 +/- 4 months)
Trial: 9032863
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose Gamma Knife treatment (surface dose 41 +/- 3 Gy, maximum dose 76 +/- 10 Gy, mean dose 53 +/- 11 Gy) in Group B (9 patients, follow-up 16 +/- 2 months)
Trial: 9032863
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose Gamma Knife treatment (surface dose 42 +/- 3 Gy, maximum dose 72 +/- 16 Gy, mean dose 54 +/- 6 Gy) in Group C (17 patients, follow-up 6 +/- 3 months)
Trial: 1523880
Drug: Conjugate vaccine
RxNorm normalized name: meningococcal conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugate vaccine (11 micrograms of each oligosaccharide and 88 micrograms of CRM 197)
Trial: 6389288
Drug: Quinine-papaverine combination
RxNorm normalized name: papaverine, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine-papaverine combination (3 X 1 coated tablet per day for four weeks)
Trial: 30714482
Drug: Self-administered therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered therapy using a smart tablet (trained with functional words)
Trial: 30714482
Drug: Self-administered therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered therapy using a smart tablet (trained with words from a picture database)
Trial: 30714482
Drug: Self-administered therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered therapy using a smart tablet (exposed but not trained)
Trial: 28102427
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg intravenous acetylsalicylic acid (ASA)
Trial: 28102427
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg intravenous acetylsalicylic acid (ASA)
Trial: 28102427
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg oral acetylsalicylic acid (ASA)
Trial: 25692350
Drug: 4-dose Zagreb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-dose Zagreb regimen
Trial: 25692350
Drug: 5-dose Essen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-dose Essen regimen
Trial: 23835708
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus pemetrexed 500 mg/m(2)
Trial: 20042475
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate 50 mg kg(‐1) i.v. as a bolus and 15 mg kg(‐1) h(‐1) by continuous infusion during the operation
Trial: 19032711
Drug: Multifamily group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifamily group therapy plus pharmacotherapy
Trial: 19032711
Drug: Individual family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual family therapy plus pharmacotherapy
Trial: 11799338
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg/day, increased to 100 mg after 4 weeks if inadequate response)
Trial: 2779240
Drug: Alcohol (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.125 g/kg of 95% ethanol)
Trial: 2779240
Drug: Alcohol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.25 g/kg of 95% ethanol)
Trial: 2779240
Drug: Alcohol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.5 g/kg of 95% ethanol)
Trial: 2779240
Drug: Concurrent schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent schedule of point presentation
Trial: 2779240
Drug: Interaction between
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interaction between alcohol and concurrent point presentation contingencies
Trial: 2779240
Drug: No alcohol
RxNorm normalized name: BENZALKONIUM CHLORIDE 0.13 g in 100 mL TOPICAL SOLUTION [Zoono Alcohol Free Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No alcohol (0 g/kg of 95% ethanol)
Trial: 177873
Drug: Radiation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation with high-dose metronidazole
Trial: 30032673
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg pyridoxine (placebo)
Trial: 12799881
Drug: Medical and
RxNorm normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical and surgical treatment for GERD
Trial: 7718367
Drug: i.m. ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.m. ketorolac 30 mg
Trial: 7006657
Drug: morphine 10
RxNorm normalized name: morphine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 10 mg
Trial: 2074061
Drug: Psychological preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological preparation (cognitive-behavioral program, 'stress inoculation')
Trial: 22104568
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT) intervention
Trial: 20032007
Drug: Fluconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (200 mg three times per week)
Trial: 11837717
Drug: Alprostadil alfadex
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprostadil alfadex at a dose of 0.05 microg/kg/min
Trial: 11837717
Drug: Alprostadil alfadex
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprostadil alfadex at a dose of 0.1 microg/kg/min
Trial: 10368359
Drug: Ibuprofen (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (1.2 g/day for 3 days)
Trial: 29924642
Drug: Ibuprofen and
RxNorm normalized name: Ibuprofen and Famotidine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen and Placebo
Trial: 31606244
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (840 mg EPA and 560 mg DHA per day)
Trial: 30206011
Drug: Traditional heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional heparin and protamine dosage based on body weight (Control group)
Trial: 22156892
Drug: Buprenorphine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (20 μg/h)
Trial: 22156892
Drug: Fentanyl (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (25 μg/h)
Trial: 17343594
Drug: Collagen-polyvinylpyrrolidone (clg-pvp)
RxNorm normalized name: triacontanyl PVP (WP-660)
DrugBank: Collagen-polyvinylpyrrolidone (DB16525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen-polyvinylpyrrolidone (clg-pvp) applied at a rate of 1.5 ml intradermically at four equi-spaced points around the ulcer.
Trial: 17343594
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline solution with polyvinylpyrrolidone) applied at a rate of 1.5 ml intradermically at four equi-spaced points around the ulcer.
Trial: 28753384
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 (D75)
Trial: 12108897
Drug: Docetaxel 100
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 100 mg/m2 (D100)
Trial: 3808504
Drug: strict management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: strict management (euglycemic: fasting blood glucose < 80 mg/dL, 1.5-hour postprandial blood glucose < 120 mg/dL)
Trial: 3808504
Drug: customary management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: customary management (fasting blood glucose ≤ 100 mg/dL, postprandial blood glucose < 140 mg/dL)
Trial: 21504883
Drug: Contact Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contact Control (CC)
Trial: 17700438
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy added to general practitioners' care
Trial: 8942589
Drug: IV droperidol
RxNorm normalized name: Droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV droperidol 1.25 mg and ondansetron 4 mg
Trial: 8942589
Drug: IV droperidol
RxNorm normalized name: Droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV droperidol 1.25 mg and saline
Trial: 2039720
Drug: Oral 8‐methoxypsoralen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 8‐methoxypsoralen photochemotherapy (PUVA) using ultraviolet fluorescent lamps with peak emission at 325 nm
Trial: 2039720
Drug: Oral 8‐methoxypsoralen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 8‐methoxypsoralen photochemotherapy (PUVA) using ultraviolet fluorescent lamps with peak emission at 352 nm
Trial: 2039720
Drug: Oral 8‐methoxypsoralen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 8‐methoxypsoralen photochemotherapy (PUVA) using ultraviolet fluorescent lamps with peak emission at 370 nm
Trial: 7129805
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg nomifensine intravenously
Trial: 7129805
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg nomifensine orally
Trial: 7129805
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg nomifensine orally
Trial: 31520608
Drug: Hygroscopic dilators
RxNorm normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hygroscopic dilators with misoprostol 400 mcg
Trial: 31520608
Drug: No hygroscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No hygroscopic dilators with misoprostol 400 mcg
Trial: 26553689
Drug: PsA‐TT (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PsA‐TT (2 doses)
Trial: 21175981
Drug: Continuous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous insulin infusion (Actrapid 2 IU/h) during dialysis
Trial: 15095806
Drug: Auditory, tactile,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auditory, tactile, visual, and vestibular (ATVV) multisensory intervention twice daily from 33 weeks postconceptional age until hospital discharge
Trial: 2198303
Drug: Buspirone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (15 mg/day, titrated to a maximum of 90 mg/day)
Trial: 2198303
Drug: Buspirone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (40 mg/day)
Trial: 30409085
Drug: Mediterranean diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean diet with 3-4 daily serves of dairy food (MedDairy)
Trial: 30905230
Drug: Canola oil
RxNorm normalized name: Canola Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canola oil (20 mL/d)
Trial: 30905230
Drug: Amaranth oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amaranth oil (20 mL/d)
Trial: 24057101
Drug: Dexamethasone (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.2 mg/kg intravenous before anesthesia)
Trial: 11317194
Drug: COER-verapamil (180-540
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COER-verapamil (180-540 mg at bedtime)
Trial: 7805631
Drug: Behavioral family-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral family-based treatment targeting parents and children for weight loss
Trial: 26160319
Drug: Intravenous midazolam-fentanyl
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam-fentanyl anaesthesia (Control)
Trial: 19081414
Drug: Transradial PCI
RxNorm normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transradial PCI with maximal antiplatelet therapy (clopidogrel and abciximab)
Trial: 16572442
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg infliximab
Trial: 9231892
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of verapamil slow release (SR) and trandolapril, administered for 8 weeks
Trial: 3884766
Drug: Immunosuppressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive treatment (prednisone plus azathioprine)
Trial: 31004493
Drug: Progressive multi-component
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive multi-component (PMC) intervention including lower extremity resistance training at 80% of a 1-repetition maximum, task-specific activities of daily living training, advanced gait and balance training, nutritional supplementation, and nursing support during transition from hospital to home
Trial: 31004493
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (UC) physical therapy
Trial: 30348145
Drug: GLP-1 RA
RxNorm normalized name: RAS
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GLP-1 RA therapy
Trial: 28002471
Drug: Omeprazole 2.5
RxNorm normalized name: omeprazole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 2.5 mg/kg/day for neonates born at less than 32 weeks of GA (n = 30)
Trial: 28002471
Drug: Omeprazole 1
RxNorm normalized name: omeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 1 mg/kg/day for neonates born at more than 32 weeks of GA (n = 24)
Trial: 16368032
Drug: Psychological interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychological interventions (cognitive behaviour therapy, counselling)
Trial: 12163777
Drug: Early hemodynamic
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early hemodynamic optimization (goals: cardiac index >4.5 L x min(‐1) x m(‐2), pulmonary artery occlusion pressure <18 mm Hg, oxygen delivery >600 mL x min(‐1) x m(‐2), oxygen consumption >170 mL x min(‐1) x m(‐2))